180 related articles for article (PubMed ID: 3593394)
1. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
Chang RS; Lotti VJ; Chen TB
Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
[TBL] [Abstract][Full Text] [Related]
3. Purification and characterization of the rat pancreatic cholecystokinin receptor.
Duong LT; Hadac EM; Miller LJ; Vlasuk GP
J Biol Chem; 1989 Oct; 264(30):17990-6. PubMed ID: 2808360
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
Chang RS; Lotti VJ; Chen TB; Kunkel KA
Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
[TBL] [Abstract][Full Text] [Related]
5. Cibacron blue-induced enhancement of agonist binding to cholecystokinin (CCK) receptors in solubilized pancreatic membranes.
Yuan DS; Wank SA; Gardner JD
Biochim Biophys Acta; 1993 Feb; 1146(1):52-8. PubMed ID: 8443227
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Talkad VD; Patto RJ; Metz DC; Turner RJ; Fortune KP; Bhat ST; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):103-16. PubMed ID: 7524683
[TBL] [Abstract][Full Text] [Related]
8. Purification of the pancreatic cholecystokinin receptor.
Szecowka J; Hallden G; Goldfine ID; Williams JA
Regul Pept; 1989 Mar; 24(3):215-24. PubMed ID: 2710962
[TBL] [Abstract][Full Text] [Related]
9. Characterization of neuronal cholecystokinin receptor by L-364,718 in Auerbach's plexus.
Zelles T; Harsing LG; Vizi ES
Eur J Pharmacol; 1990 Mar; 178(1):101-4. PubMed ID: 2332026
[TBL] [Abstract][Full Text] [Related]
10. Direct demonstration of three different states of the pancreatic cholecystokinin receptor.
Talkad VD; Fortune KP; Pollo DA; Shah GN; Wank SA; Gardner JD
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1868-72. PubMed ID: 8127897
[TBL] [Abstract][Full Text] [Related]
11. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
[TBL] [Abstract][Full Text] [Related]
12. Solubilization and characterization of CCK receptors from mouse pancreas.
Szecòwka J; Goldfine ID; Williams JA
Regul Pept; 1985 Mar; 10(2-3):71-83. PubMed ID: 2986202
[TBL] [Abstract][Full Text] [Related]
13. Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization.
Saita Y; Yazawa H; Honma Y; Nishida A; Miyata K; Honda K
Eur J Pharmacol; 1994 Oct; 269(2):249-54. PubMed ID: 7851501
[TBL] [Abstract][Full Text] [Related]
14. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
15. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
[TBL] [Abstract][Full Text] [Related]
16. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists.
Hill DR; Campbell NJ; Shaw TM; Woodruff GN
J Neurosci; 1987 Sep; 7(9):2967-76. PubMed ID: 3625281
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
18. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
Durieux C; Ruiz-Gayo M; Roques BP
Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
[TBL] [Abstract][Full Text] [Related]
19. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Pandya PK; Huang SC; Talkad VD; Wank SA; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):117-26. PubMed ID: 7948036
[TBL] [Abstract][Full Text] [Related]
20. Binding sites for 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass.
Hill DR; Shaw TM; Woodruff GN
Neurosci Lett; 1988 Jun; 89(2):133-9. PubMed ID: 3134624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
